The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome
The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome: A Randomized, Double-Blind Placebo Controlled Clinical Trial
Sponsor: Pharmabiotix Inc
This NA trial investigates Irritable Bowel Syndrome With Diarrhea and is currently completed. Pharmabiotix Inc leads this study, which shows 8 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jul 2020 — Jan 2021 [monthly]
Completed NA
-
Nov 2019 — Jul 2020 [monthly]
Completed NA
Status: Unknown Status → Completed · Phase: PHASE2 → NA
▶ Show 3 earlier versions
-
Oct 2018 — Nov 2019 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pharmabiotix Inc
- University of Alberta
For direct contact, visit the study record on ClinicalTrials.gov .